Barnes & Noble Education Reports Third Quarter Fiscal Year 2025 Financial Results BNC First Day® Program Revenues Increased 21% YOY to $222 Million Total Revenue Growth of 2% and Gross Comparable Store Sales Growth of 7% Net Income Improves by $17 Million to $7 Million Adjusted EBITDA Improves by $6 Million to $27 Million BASKING RIDGE, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- , (“Barnes & Noble Education,” “BNED,” the “Company,” “we,” “us,” “our”), a leading solutions provider for the education industry, today reported sales and earnings for the third quarter ended on January 25, 202...
Barnes & Noble Education Strengthens Leadership Team with the Appointment of Christopher Neumann as General Counsel & Corporate Secretary and Gary Luster as Chief Accounting Officer BASKING RIDGE, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- (NYSE: BNED), a leading solutions provider for the education industry, today announced the appointment of Christopher Neumann as General Counsel & Corporate Secretary and Gary Luster as Chief Accounting Officer, effective March 3, 2025. Christopher Neumann – General Counsel & Corporate SecretaryMr. Neumann joins BNED from Six Flags — a NYSE listed publi...
Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C New website launched in honor of Rare Disease Day, Feb. 28, 2025 Awareness campaign includes educational resources and testing information for individuals with suspected NPC. CELEBRATION, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies to people living with rare disease, today announced, on Rare Disease ...
Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million CELEBRATION, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $150 million upon the closing of the transaction, which is expected to take place within 30 to 45 days...
Zevra to Report 2024 Fourth Quarter and Full Year Financial Results Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the fourth quarter and full year 2024 on Tuesday, Mar. 11, 2025. The Company will issue a news release after the market closes and host a conference call/audio webcas...
Zevra to Participate at Upcoming Investor Conferences CELEBRATION, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will participate at the following March events: TD Cowen 45th Annual Health Care Conference on Wednesday, Mar. 5, 2025, at 10:30 a.m. ET.37th Annual ROTH Conference on Monday, Mar. 17, 2025, at 1:00 p.m. PT. Additionally, management will be available for one...
A director at Paycom Software Inc sold 1,500 shares at 210.570USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™ Zevra to receive a 2025 New Treatment Award for MIPLYFFA™ at the 21st Annual WORLDSymposium Eight abstracts discussing data and clinical experience associated with MIPLYFFA accepted for poster presentation, with one poster selected for oral presentation by Dr. Eugen Mengel CELEBRATION, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that eight abstracts discussing data and clinical ex...
Zevra Therapeutics to Participate at Upcoming Investor Conferences CELEBRATION, Fla., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that members of Zevra’s executive leadership team will participate in the following February events. Guggenheim Securities SMID Cap Biotechnology Conference on Wednesday, Feb. 5, 2025, at 2:30 p.m. ET.Oppenheimer & Co. 35th Annual Healthcare Life Sciences Conference on Wednesday, Feb. 12, 2025, at 3:20 p.m. ET. Additionally, managemen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.